High dose amantadine therapy may cause increased falling in patients with Parkinson's disease: A case report.
作者信息
Dames Bridget, Karl Jessica A, Verhagen Metman Leo
机构信息
Rush University, Department of Neurological Sciences, Movement Disorder Section, 1725 W. Harrison St. Suite 755, Chicago, IL 60612, United States of America.
University of Toledo College of Medicine and Life Sciences, 3000 Arlington Ave, Toledo, OH 43614, United States of America.
出版信息
Clin Park Relat Disord. 2020 Feb 22;3:100045. doi: 10.1016/j.prdoa.2020.100045. eCollection 2020.
Abstract
摘要
相似文献
1
High dose amantadine therapy may cause increased falling in patients with Parkinson's disease: A case report.
Clin Park Relat Disord. 2020 Feb 22;3:100045. doi: 10.1016/j.prdoa.2020.100045. eCollection 2020.
2
Plasma amantadine concentrations in patients with Parkinson's disease.
Parkinsonism Relat Disord. 2009 Jun;15(5):351-3. doi: 10.1016/j.parkreldis.2008.08.005. Epub 2008 Sep 27.
3
Amantadine-induced myoclonus in a patient with progressive supranuclear palsy.
Age Ageing. 2012 Sep;41(5):695-6. doi: 10.1093/ageing/afs043. Epub 2012 Mar 15.
4
[Edemas and myocloni concerning a patient with Parkinson's disease treated by amantadine (author's transl)].
Encephale. 1980;6(4):381-4.
5
Utilization Patterns of Amantadine in Parkinson's Disease Patients Enrolled in the French COPARK Study.
Drugs Aging. 2020 Mar;37(3):215-223. doi: 10.1007/s40266-019-00740-2.
6
Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson's Disease.
Neurotox Res. 2016 Jul;30(1):88-100. doi: 10.1007/s12640-016-9618-4. Epub 2016 Apr 6.
7
Urinary monoamine metabolite excretion in disorders of movement. Effects of amantadine and levodopa.
J Neurol Sci. 1977 Jun;32(2):219-25. doi: 10.1016/0022-510x(77)90237-4.
8
An updated meta-analysis of amantadine for treating dyskinesia in Parkinson's disease.
Oncotarget. 2017 May 5;8(34):57316-57326. doi: 10.18632/oncotarget.17622. eCollection 2017 Aug 22.
9
[Treatment of Parkinson's disease with multiple drugs].
Nihon Rinsho. 1997 Jan;55(1):59-64.
10
Memantine-induced myoclonus and delirium exacerbated by trimethoprim.
Ann Pharmacother. 2008 Mar;42(3):443-7. doi: 10.1345/aph.1K619. Epub 2008 Feb 26.
引用本文的文献
1
Amantadine-Induced Craniofacial Myoclonus: Distinctive Iatrogenic Dysarthria in Parkinson's Disease.
Mov Disord Clin Pract. 2023 Jul 14;10(9):1408-1413. doi: 10.1002/mdc3.13828. eCollection 2023 Sep.
2
Myoclonus Secondary to Amantadine: Case Report and Literature Review.
Clin Pract. 2023 Jul 20;13(4):830-837. doi: 10.3390/clinpract13040075.
3
Falls in Parkinson's disease: the impact of disease progression, treatment, and motor complications.
Dement Neuropsychol. 2022 Apr-Jun;16(2):153-161. doi: 10.1590/1980-5764-DN-2021-0019. Epub 2022 Apr 29.
本文引用的文献
1
Orthostatic hypotension and REM sleep behaviour disorder: impact on clinical outcomes in α-synucleinopathies.
J Neurol Neurosurg Psychiatry. 2019 Nov;90(11):1257-1263. doi: 10.1136/jnnp-2019-320846. Epub 2019 May 29.
2
Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.
Mult Scler. 2019 Apr;25(4):601-609. doi: 10.1177/1352458518754716. Epub 2018 Jan 25.
3
Parkinson's disease.
Subcell Biochem. 2012;65:389-455. doi: 10.1007/978-94-007-5416-4_16.
4
Amantadine improves gait in PD patients with STN stimulation.
Parkinsonism Relat Disord. 2013 Mar;19(3):316-9. doi: 10.1016/j.parkreldis.2012.11.005. Epub 2012 Dec 6.
5
Amantadine-induced cortical myoclonus.
Neurology. 2001 Jan 23;56(2):279-80. doi: 10.1212/wnl.56.2.279.
6
Acute delirium after withdrawal of amantadine in Parkinson's disease.
Neurology. 1998 May;50(5):1456-8. doi: 10.1212/wnl.50.5.1456.
7
Toxic effects of amantadine in patients with renal failure.
Can Med Assoc J. 1979 Mar 17;120(6):695-8.
Zotero 插件